arrow
G

Gregory P. Geba

regeneron pharmaceuticals inc
H指数:36
被引数:7,777

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data

将碱性磷酸酶鉴定为抗NGF治疗相关关节病的一种潜在生物标志物:机器学习辅助的临床试验数据分析

2025-12-010
OAAI
The Effects of Fasinumab on Peripheral Nerve Function and Ganglion Anatomy: Results From a Randomized, Double-Blind, Placebo-Controlled Study in Patients With Pain Due to Osteoarthritis of the Knee or Hip, and a Series of Nonclinical Studies

fasinumab对周围神经功能及神经节解剖结构的影响:来自一项在因膝或髋关节骨关节炎疼痛患者中进行的随机、双盲、安慰剂对照研究以及一系列非临床研究的成果

2025-11-010
OAAI
The Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results from the ODYSSEY OUTCOMES Trial

PCSK9抑制剂Alirocumab在疑似家族性高胆固醇血症或III型高脂蛋白血症患者中的疗效:ODYSSEY OUTCOMES试验结果

2024-11-120
PRE
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies

Casirivimab和Imdevimab治疗可降低血清阳性的非中和或临界中和抗体的住院新型冠状病毒肺炎患者的病毒载量并改善临床结局

MBIO
IF4.7
2022-12-207
OAAI
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

Casirivimab和Imdevimab用于治疗住院新型冠状病毒肺炎患者

2022-07-2733
OAAI
Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail
2021-06-2325
OAAI
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
2020-09-0899
OAAI